Pharma BD Deal Intelligence
BI ran Zantac OTC profitably for 11 years and exited cleanly in 2017 via the Sanofi swap - but the carcinogen (NDMA) mass-tort wave that hit in 2019-2020 pulled BI back in as a former manufacturer, and it lost a 2023 arbitration seeking indemnification from Sanofi.
Full analysis, sources & comparables →Zantac is an excellent strategic fit that complements our existing OTC franchise and provides us with leading brands in the two largest gastrointestinal (GI)…
Boehringer Ingelheim acquires US OTC Zantac rights from J&J/Pfizer for $509.5M, expanding its self-medication footprint as the eighth-largest global OTC…
The companies have agreed to sell Pfizer's Zantac H-2 blocker business to Boehringer Ingelheim... The order's terms will ensure that competition will be…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
OTC H-2 blocker rights divested per FTC order; $509.5M cash
BI ran Zantac OTC profitably for 11 years and exited cleanly in 2017 via the Sanofi swap - but the carcinogen (NDMA) mass-tort wave that hit in 2019-2020 pulled BI back in as a former manufacturer, and it lost a 2023 arbitration seeking indemnification from Sanofi.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals / J&J/Pfizer (US OTC Zantac rights) (this deal) | 2006 | $510M | 42 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| UCB SA / Schwarz Pharma AG | 2006 | $5.6B | 80 |
← Browse all deals · How we score deals
More: 2006 deals